Prospective Grant of Exclusive License: Immunotoxins With In-Vivo T Cell Suppressant Activity and Methods of Use and Immunotoxins

Riepilogo

This notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(I) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the inventions embodied in U.S. Patent Number 5,167,956, and entitled; ``Immunotoxins With In-Vivo T Cell Suppressant Activity and Methods of Use'', Patent Applications USSN 08/308,730, 60/008,104 and 60/015,459, and corresponding U.S. and foreign patent applications, all entitled; ``Immunotoxins With In-Vivo T Cell Suppressant Activity And Methods Of Use'' and U.S. Patent Number 5,208,021, and entitled; ``Immunotoxins'' and corresponding foreign patent applications to Sandoz Pharma Ltd., Basel, Switzerland. The patent rights for NIH inventors in these inventions have been assigned to the United States of America. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the